Drug Search Results
More Filters [+]

BAY79-4620

Alternative Names: bay79-4620, bay794620, bay79 4620
Latest Update: 2015-01-21
Latest Update Note: Clinical Trial Update

Product Description

antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9; selective CAIX antibody-drug conjugate CAIX-ADC (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22147747/)

Mechanisms of Action: Tubulin Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BAY79-4620

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01028755

P1

Completed

Oncology Solid Tumor Unspecified

2013-04-01

NCT01065623

P1

Terminated

Oncology Solid Tumor Unspecified

2010-08-01

Recent News Events

Date

Type

Title